Literature DB >> 25547681

Recent progress in dengue vaccine development.

Jianchun Wei1, Hui Chen, Jing An.   

Abstract

Dengue virus (DENV) has four distinct serotypes. DENV infection can result in classic dengue fever and life-threatening dengue hemorrhagic fever/dengue shock syndrome. In recent decades, DENV infection has become an important public health concern in epidemic-prone areas. Vaccination is the most effective measure to prevent and control viral infections. However, several challenges impede the development of effective DENV vaccines, such as the lack of suitable animal models and the antibody-dependent enhancement phenomenon. Although no licensed DENV vaccine is available, significant progress has been made. This review summarizes candidate DENV vaccines from recent investigations.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25547681      PMCID： PMC8206420          DOI： 10.1007/s12250-014-3542-7

Source DB:  PubMed          Journal:  Virol Sin        ISSN： 1995-820X            Impact factor:   4.327


  79 in total

1.  Innate and adaptive cellular immunity in flavivirus-naïve human recipients of a live-attenuated dengue serotype 3 vaccine produced in Vero cells (VDV3).

Authors:  Violette Sanchez; Sophie Gimenez; Brian Tomlinson; Paul K S Chan; G Neil Thomas; Remi Forrat; Laurent Chambonneau; Florence Deauvieau; Jean Lang; Bruno Guy
Journal:  Vaccine       Date:  2006-04-04       Impact factor: 3.641

Review 2.  Progress in development of a live-attenuated, tetravalent dengue virus vaccine by the United States Army Medical Research and Materiel Command.

Authors:  Bruce L Innis; Kenneth H Eckels
Journal:  Am J Trop Med Hyg       Date:  2003-12       Impact factor: 2.345

3.  Development of Sanofi Pasteur tetravalent dengue vaccine.

Authors:  Jean Lang
Journal:  Rev Inst Med Trop Sao Paulo       Date:  2012-10       Impact factor: 1.846

Review 4.  Immunity to dengue virus: a tale of original antigenic sin and tropical cytokine storms.

Authors:  Alan L Rothman
Journal:  Nat Rev Immunol       Date:  2011-07-15       Impact factor: 53.106

5.  Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: Phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes.

Authors:  Farshad Guirakhoo; Scott Kitchener; Dennis Morrison; Remi Forrat; Karen McCarthy; Richard Nichols; Sutee Yoksan; Xiaochu Duan; Thomas H Ermak; Niranjan Kanesa-Thasan; Philip Bedford; Jean Lang; Marie-Jose Quentin-Millet; Thomas P Monath
Journal:  Hum Vaccin       Date:  2006-03-15

6.  Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial.

Authors:  Arunee Sabchareon; Derek Wallace; Chukiat Sirivichayakul; Kriengsak Limkittikul; Pornthep Chanthavanich; Saravudh Suvannadabba; Vithaya Jiwariyavej; Wut Dulyachai; Krisana Pengsaa; T Anh Wartel; Annick Moureau; Melanie Saville; Alain Bouckenooghe; Simonetta Viviani; Nadia G Tornieporth; Jean Lang
Journal:  Lancet       Date:  2012-09-11       Impact factor: 79.321

Review 7.  Recent clinical experience with vaccines using MPL- and QS-21-containing adjuvant systems.

Authors:  Nathalie Garçon; Marcelle Van Mechelen
Journal:  Expert Rev Vaccines       Date:  2011-04       Impact factor: 5.217

8.  Development of a recombinant tetravalent dengue virus vaccine: immunogenicity and efficacy studies in mice and monkeys.

Authors:  David E Clements; Beth-Ann G Coller; Michael M Lieberman; Steven Ogata; Gordon Wang; Kent E Harada; J Robert Putnak; John M Ivy; Michael McDonell; Gary S Bignami; Iain D Peters; Julia Leung; Carolyn Weeks-Levy; Eileen T Nakano; Tom Humphreys
Journal:  Vaccine       Date:  2010-01-22       Impact factor: 3.641

9.  Phase 1 trial of the dengue virus type 4 vaccine candidate rDEN4{Delta}30-4995 in healthy adult volunteers.

Authors:  Peter F Wright; Anna P Durbin; Stephen S Whitehead; Mine R Ikizler; Susan Henderson; Joseph E Blaney; Bhavin Thumar; Sharon Ankrah; Michael T Rock; Brett A McKinney; Brian R Murphy; Alexander C Schmidt
Journal:  Am J Trop Med Hyg       Date:  2009-11       Impact factor: 2.345

10.  Dengue virus type 3 vaccine candidates generated by introduction of deletions in the 3' untranslated region (3'-UTR) or by exchange of the DENV-3 3'-UTR with that of DENV-4.

Authors:  Joseph E Blaney; Neeraj S Sathe; Laura Goddard; Christopher T Hanson; Tammy A Romero; Kathryn A Hanley; Brian R Murphy; Stephen S Whitehead
Journal:  Vaccine       Date:  2007-12-26       Impact factor: 3.641
View more
  1 in total

Review 1.  Dengue epidemiology and pathogenesis: images of the future viewed through a mirror of the past.

Authors:  Rashedul Islam; Mohammed Salahuddin; Md Salahuddin Ayubi; Tahmina Hossain; Apurba Majumder; Andrew W Taylor-Robinson; Abdullah Mahmud-Al-Rafat
Journal:  Virol Sin       Date:  2015-10-20       Impact factor: 4.327
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.